Insider Selling: Axon Enterprise (NASDAQ:AXON) Director Sells 157 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Jeri Williams sold 157 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total value of $76,930.00. Following the sale, the director directly owned 1,159 shares of the company’s stock, valued at approximately $567,910. This represents a 11.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Axon Enterprise Price Performance

Shares of NASDAQ AXON traded down $6.23 during mid-day trading on Thursday, reaching $502.18. The company had a trading volume of 512,564 shares, compared to its average volume of 1,005,583. The company has a 50-day moving average price of $524.40 and a two-hundred day moving average price of $603.77. The stock has a market cap of $40.38 billion, a PE ratio of 330.38, a P/E/G ratio of 10.81 and a beta of 1.46. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.08 earnings per share. On average, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Barclays lowered their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Piper Sandler decreased their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target on the stock in a research report on Tuesday, January 6th. UBS Group decreased their price objective on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Needham & Company LLC dropped their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $762.93.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Axon Enterprise in the 4th quarter valued at approximately $480,000. NewEdge Advisors LLC grew its position in Axon Enterprise by 41.1% in the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after acquiring an additional 668 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Axon Enterprise in the 2nd quarter valued at $284,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Software & Services momentum — Multiple analyst pieces highlight ~40% growth in Axon’s Software & Services in 2025 and rising subscription revenue, which supports recurring-margin upside for the business. Read More.
• Positive Sentiment: Municipal adoption — A $1.97M Decatur, IL grant to upgrade police tech underscores continued municipal demand that drives both hardware and recurring software contracts. Read More.
• Positive Sentiment: Institutional/information flow — Coverage noting interest from funds (e.g., Baron Opportunity Fund mention) and “trending” status can attract buyer attention and liquidity. Read More.
• Neutral Sentiment: Trending / aggregator stories — Multiple Zacks/Yahoo/MarketBeat rundowns raise awareness but are not new fundamental catalysts. Read More.
• Neutral Sentiment: Short-interest reporting glitch — Recent short-interest posts show “0 shares” and NaN changes; this appears to be a data/reporting issue rather than meaningful short-seller pressure.
• Negative Sentiment: Valuation / “priced in” debate — Commentary (Seeking Alpha and others) argues Axon’s strong growth may already be priced into the stock, increasing sensitivity to any growth-miss or multiple compression. Read More.
• Negative Sentiment: Insider sale — Director Erika Nardini sold 198 shares (~$506.58 avg), reducing her stake ~9.2%; small in dollars but often viewed negatively by sentiment-driven traders. Read More.
• Negative Sentiment: Near-term sentiment drag — Media pieces highlighting a recent multi-day slide and market-cap pullback feed skeptical narratives that can pressure the stock in the short term. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.